BETR.CNBetterLife Pharma Inc.
The schedule
- Thu22Oct
Anticipated capital raise to sustain clinical progression for BETR-001. A favorable resolution limits dilution near $0.32, while a deeply discounted offering with heavy warrant coverage pushes the stock to a $0.15 fallback.
- Thu3Dec
Regulatory update for the core non-hallucinogenic LSD derivative program. Successful IND clearance targets $0.28, whereas a clinical hold or FDA regulatory delay drops shares to $0.08.
- Thu3Dec
Initial safety and tolerability data for the BETR-001 program. A clean safety profile with early signals of target engagement sparks a re-rating to $0.40, while serious adverse events risk a plunge to $0.05.
- Thu25Mar
Quarterly financial update detailing early clinical trial progress and updated cash burn. Constructive commentary on patient enrollment points to $0.38, while burn rates exceeding estimates trigger a slide to $0.18.
Past
- Fri21Aug
Actual outcome: Bull · $0.31 at outcome
BetterLife Pharma Inc. (BETR.CN) announced securing CAD $2 million in new funding, which significantly boosted investor confidence and drove a substantial price increase. This capital infusion likely supports ongoing clinical trials and product development, aligning with the stock's strong performance over the 75-day period. The move reflects positive market sentiment toward the company's growth potential. [Market retrospective · Long-Term (31–75 days)] Missed anticipation: +453.8% from 2026-04-30 to 2026-08-20 (~6.8σ vs typical 75d vol). Target evaluation date 2026-09-21 (not yet reached as of 2026-08-20). Confidence 95%.
BetterLife Pharma Inc. (BETR.CN) announced securing CAD $2 million in new funding, which significantly boosted investor confidence and drove a substantial price increase. This capital infusion likely supports ongoing clinical trials and product development, aligning with the stock's strong performance over the 75-day period. The move reflects positive market sentiment toward the company's growth potential. [Market retrospective · Long-Term (31–75 days)] Missed anticipation: +453.8% from 2026-04-30 to 2026-08-20 (~6.8σ vs typical 75d vol). Target evaluation date 2026-09-21 (not yet reached as of 2026-08-20). Confidence 95%.